JPRN-UMIN000015769招募中1 期
Clinical trial of Novo-TTF-100A for recurrent glioblastoma - Novo-TTF for recurrent GBM
Osaka Medical College, Cancer Center0 个研究点目标入组 20 人开始时间: 2014年11月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with the infra-tentorial lesions. 2) Patients received with pacemakers or shuntting devices with magnet actions. 3) Pateients with sever systemic complications, necessary for hospitalization. 4) Patients with unhealed scalp wound. 5) Patients with infectious diseses,necessary for antibiotics, so on. 6) Female patients in definitive or possible pregnancy or in breast-feeding. 7) Other patients whose participation in the present study is considered inappropriate by a Principal Investigator or Clinical Investigator.
研究者
相似试验
招募中
1 期
A First-In-Human Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancercolorectal cancer2024-512296-13-00NEOGAP Therapeutics AB16
尚未招募
不适用
A phase 2 trial to assess efficacy and safety of Enhertu in HER2-mutant advanced lung cancer patients with asymptomatic brain metastasesNeoplasmsKCT0009147Yonsei University Health System, Severance Hospital27
已完成
1 期
Mesenchymal Stem Cells Transplantation in newly diagnosed Type-1 Diabetes PatientsDiabetes.Insulin-dependent diabetes mellitusIRCT2016070428786N1Royan Institute20
已完成
3 期
Title: Clinical trial of efficacy of Trans cranial direct current stimulation (TDCS) in reducing post-traumatic stress signs in military post-traumatic stress disorderpost-traumatic stress disorder.Post-traumatic stress disorder (PTSD):rises as a delayed or protracted response to a stressful event or situation (of either brief or long duration) of an exceptionally threatening or catastrophic nature, which is likely to cause pervasive distress in almIRCT20150427021965N9Rasht University of Medical Sciences60
尚未招募
不适用
A phase I clinical trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS)myelodysplasiamyelodysplastic syndroom10018865NL-OMON30154niversitair Medisch Centrum Sint Radboud18